Anti-PD-1 (Spartalizumab) humanized Antibody

CATALOG NO.: A2131-100 (100 µg)

BACKGROUND DESCRIPTION: Spartalizumab is a humanized IgG4 monoclonal antibody developed by Novartis for the treatment of solid tumors as well as lymphomas. They act as negative immune regulators of programmed death-1 (PD-1), a transmembrane protein belonging to the immunoglobulin (Ig) superfamily. When administered, Spartalizumab binds to T-cells expressing PD-1 and thereby blocks the interaction between PD-1 and its ligands, programmed cell death 1 ligand 1 (PD-L1) and ligand 2 (PD-L2). Blocking the interaction disrupts PD-1 mediated signaling and results in activation of cytotoxic T lymphocytes and T cell mediated immune responses and thus inhibits the growth and size of the tumors. Ongoing clinical trials are evaluating the efficacy of this antibody for the treatment of metastatic pancreatic cancer and melanoma.

ALTERNATE NAMES: PDCD1, PD1, CD279, SLEB2, hPD-1, hPD-I, PDR 001, PDR001

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: CHO cells / Human IgG4

IMMUNOGEN: Spartalizumab

FORM: Liquid

FORMULATION: In PBS buffer, pH 7.2

STORAGE CONDITIONS: Undiluted antibody solution should be stored at 4°C in the dark and avoid freezing the solution

APPLICATIONS AND USAGE: In vivo studies

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:
- Anti-PD-L1 (Durvalumab), Human IgG1 Antibody (A2109)
- Anti-PD-1 (Pembrolizumab) Biotinylated Antibody (A2073)
- Anti-PD-1 (CD279), Rabbit Monoclonal Antibody (A1825)
- Anti-PD-L1 (Atezolizumab), Humanized Antibody (A1305)
- Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)

FOR RESEARCH USE ONLY! Not to be used on humans.